David Nikzad’s Noted “Utopian Holding Company” Orthogonal Thinker Has Relocated to Miami to Lead for the Future

by

Share

Miami, Florida – November 1, 2021 – Orthogonal Thinker, a self-described “Utopian Holding Company” led by noted investor and exec David Nikzad, is pleased to announce its move to the hottest new venture market – Miami, Florida. This move has invigorated the company, leading to 15 new deals inked since he arrived in early July. Orthogonal makes strategic investments and joint-ventures with companies which contribute to the Orthogonal eco-system of companies in new and emerging industries.

Nikzad, founder and CEO of Orthogonal Thinker notes, “Part of the secret of my success is that I’m just enough ahead of the curve, and my recent move to Miami is just another example of that. We are so excited to be part of the growth of the South Florida startup scene, which is so inclusive of the verticals we specialize in – space, crypto, cannabis, psychedelics, and clean food.”

Orthogonal’s most exciting company is their subsidiary Ei.Ventures. Ei has had an amazing year, cresting $20M committed with their Reg A. As part of their research and development into natural psychedelic compounds, EI recently announced via Forbes that they have partnered with transdermal delivery powerhouse Tioga Research to develop a transdermal patch for sustained delivery of psilocin, the active ingredient in psilocybin mushrooms, for mental health applications.

As part of Ei’s dual track approach, they are planning to launch their line of functional mushroom MANA nutraceuticals imminently, and a functional beverage with mushroom botanicals in early 2022.

Building companies through crowdfunding has always been part of Orthogonal’s DNA, as some early investments included crowdfunders WeFunder, RealCrowd, DealMaker, and Republic. Through this experience and the recent success of Ei’s Reg A, Orthogonal is now positioned as a leader in the Reg A fundraising space and have vertically integrated their internal team to manage Reg A raises for their portfolio companies.

Nikzad adds, “We couldn’t be more bullish on Miami and are looking to show our gratitude for the wonderful reception we’ve gotten in South Florida by bringing funding from all levels of investors to this growing region.”

Share

Emotional Intelligence Ventures Reg A Raise at $20M, Company Pursues Psylocibin Transdermal Delivery Research, Plans Nutraceutical Mushroom Supplements Launch

by

Share

Miami, Florida – October 18, 2021 – Emotional Intelligence Ventures, led by noted investor and exec David Nikzad, are pleased to announce their Regulation A raise is currently at $20,114,949, with more investors coming in daily. Ultimately, they are looking to raise a maximum of $49,999,999, and believe this is a completely doable goal. A Regulation A offering allows for retail investors to invest in pre-public and private companies. The net proceeds of the offering will be used to accelerate the development and distribution of Ei’s medicinal and functional mushroom product lines.

David Nikzad, founder and CEO of Ei.Ventures notes, “We are so committed to the nonaccredited investor, that we are pursuing a Regulation A offering.” Adding, “As I’ve been fortunate to invest early in numerous companies like Airbnb, Betterment, and Vidyard, and three equity crowdfunding platforms (WeFunder, RealCrowd, Republic), I’m really passionate about democratizing investment opportunities so any investor can reap the rewards, and take all of the risks of early investment in game-changing companies.”

As part of their research and development into natural psychedelic compounds, EI recently announced via Forbes that they have partnered with transdermal delivery powerhouse Tioga Research to develop a transdermal patch for sustained delivery of psilocin, the active ingredient in psilocybin mushrooms, for mental health applications.

The company believes this announcement along with the increasing interest in the psychedelic medicine for mental health space, and a rising tide of medicalization, decriminalization, and legalization of psychedelic mushrooms are driving interest in the overall psychedelic medicine space, and Ei.Ventures in particular.

On Monday October 4, the Seattle City Council voted to decriminalize the non-commercial possession and cultivation of many psychedelics, including mushrooms, for “religious, spiritual, healing, or personal growth practices.” Council members passed the resolution unanimously, with a 9-0 vote. This makes Seattle the largest city in the United States to decriminalize psychedelic plants and fungi.

As part of Ei’s dual track approach, they are planning to launch their line of functional mushroom MANA nutraceuticals in early 2022. They are creating proprietary formulations using a unique formulation process for enhanced bioavailability and efficacy. These products target cognition and immune system; energy, vitality, mood, sleep, and weight loss; mental and physical optimization for micro dosers; nootropic or Smart Drugs; and joint & muscle pain.

Share

Ei.Ventures Announce Engagement With Tioga Research to Develop Transdermal Patch for Psilocin Delivery

by

Share

Maui, Hawaii/San Diego, California – August 26, 2021 – Noted psychedelic medicine start-up Ei.Ventures is excited to announce their engagement with Tioga Research to develop a transdermal patch for sustained delivery of psilocin, the active ingredient in psilocybin mushrooms, for mental health applications.

David Nikzad, the CEO of Ei.Ventures notes, “we are over the moon to join with one of the top transdermal delivery research specialists, Tioga Research, to begin developing products that could potentially help millions of people manage their mental health issues – depression, anxiety, PTSD, etc. with a patch. Additionally, with the increasing legality and popularity of psilocybin mushrooms, transdermal delivery could become a popular method for micro-dosing which helps with mental clarity and mood stabilization as well.”

John M. Newsam, CEO of Tioga Research adds, “By working with Ei.Ventures on a blue sky project of this nature, we will deploy our proprietary technologies and deep expertise to address key psilocin formulation issues, such as delivery and stability. A transdermal delivery route can circumvent issues with oral administration, such as nausea.”

EI.Ventures is focused on developing botanical active pharmaceutical ingredients for the psychedelic supply chain, novel psychedelic compounds for various indications, and unique delivery mechanisms and treatment protocols. In addition to their future regulated psychedelic line, Ei Ventures will release their MANA range of functional mushroom nutraceuticals for improving well-being and health in Q3 2021.

Tioga Research supports the research and early development of skin-applied products, offering formulation innovation, skin permeation screening, and GLP IVRT/IVPT services. In addition, the company has pioneered high throughput experimentation (“HTE”) technologies for screening skin delivery. Tioga Research was founded in 2011 to support innovations in skin-applied products, especially topical and transdermal drug products, including skincare products and cosmetics. With headquarters and laboratory operations in San Diego, CA, and a business presence in the UK to support clients in Europe, Tioga Research has become a preferred service provider for an impressive portfolio of clients across the Americas, Europe, and Asia. Tioga Research has been a subsidiary of Encube Ethicals since early 2020, enabling clients to leverage the combined strengths of both organizations from early formulation innovation to commercial manufacturing.

Share